Egetis Therapeutics AB (PDPHF)
Market Closed
13 Jul, 20:00
$
0. 64
0
0%
$
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
- Eps
$ 0.64
Previous Close Want to track PDPHF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
PDPHF closed Monday higher at $0.64, an increase of 0% from Friday's close, completing a monthly increase of 0% or $0. Over the past 12 months, PDPHF stock gained 0%.
PDPHF is not paying dividends to its shareholders.
The last earnings report, released on Apr 28, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on XSTO (SEK).
PDPHF Chart
Egetis Therapeutics AB (PDPHF) FAQ
What is the stock price today?
The current price is $0.64.
On which exchange is it traded?
Egetis Therapeutics AB is listed on OTC PINK.
What is its stock symbol?
The ticker symbol is PDPHF.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Egetis Therapeutics AB ever had a stock split?
No, there has never been a stock split.
Egetis Therapeutics AB Profile
| Biotechnology Industry | Healthcare Sector | Mr. Nicklas Westerholm CEO | OTC PINK Exchange | SE0003815604 ISIN |
| SE Country | 44 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Egetis Therapeutics AB (publ) is a noteworthy player in the pharmaceutical landscape, primarily concentrating on advancing projects within the late stages of development. This targeted focus is on addressing serious diseases that currently lack sufficient medical solutions, particularly within the orphan drug category. Originally established under the name PledPharma AB (publ), the company underwent a significant rebranding to Egetis Therapeutics AB (publ) in December 2020. Founded in 2006, and operating out of Stockholm, Sweden, Egetis has carved a niche for itself by tackling unmet medical needs in the healthcare sector.
Products and Services
- Aladote - Aladote represents a significant advancement in the treatment of acetaminophen/paracetamol poisoning, aimed at mitigating the risk of acute liver injury. Currently navigating the stage of phase IIb/III clinical trial, Aladote showcases Egetis Therapeutics AB’s dedication to innovating within the field of critical care medicine.
- Emcitate - Emcitate addresses a very specific and challenging medical condition known as MCT8 deficiency. This condition is characterized by its highly debilitating nature and the startling absence of available treatments. Through the development of Emcitate, Egetis Therapeutics AB is paving the way in providing hope and potential relief to patients suffering from this rare disease.
Contact Information
Address: Klara Norra Kyrkogata 26, Stockholm, Sweden, 111 22
Phone: 46 86 79 72 10
Website: https://www.egetis.com
